Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of many cancers and have demonstrated their potential as 'cancer terminators'. However, ICI treatment also has constraints, such as its immune-related adverse events (irAEs) and therapeutic resistance. These drawbacks are gradually being overcome through better knowledge of the immune system, history of disease, duration of treatment, combinational drug regimes, adequate biomarkers, and effective patient response monitoring. In this review, we discuss the present ICI therapy landscape and its therapeutic outcomes for various diseases. We also highlight biomarkers related to the ICI response.

中文翻译：

---

免疫检查点抑制剂：一种有前途的抗癌治疗方法。

免疫检查点抑制剂（ICIs）正在彻底改变许多癌症的治疗方法，并证明了其作为“癌症终结者”的潜力。但是，ICI治疗也有一些局限性，例如其免疫相关不良事件（irAEs）和治疗耐药性。通过更好地了解免疫系统，疾病史，治疗时间，联合用药方案，适当的生物标志物以及有效的患者反应监测，这些缺点将逐渐得到克服。在这篇综述中，我们讨论了目前ICI治疗的前景及其对各种疾病的治疗效果。我们还重点介绍了与ICI反应相关的生物标志物。